Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Perinatal insights into human T-lymphotropic virus 1 in western French Guiana: Unmasking a silent disease.

European journal of obstetrics, gynecology, and reproductive biology·2026

Same author

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Journal of the National Cancer Institute·2026

Same author

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

European journal of cancer (Oxford, England : 1990)·2026

Same author

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

International journal of cancer·2026

Same author

[Is geriatric oncology a recognized speciality?]

La Revue du praticien·2026

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Motesanib diphosphate in progressive differentiated thyroid cancer.

Steven I Sherman¹, Lori J Wirth, Jean-Pierre Droz

¹Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M.D. Anderson Cancer Center, Houston 77230-1402, USA. sisherma@mdanderson.org

The New England Journal of Medicine

|July 4, 2008

Summary

Motesanib diphosphate showed efficacy in advanced differentiated thyroid cancer, inducing partial responses and stable disease in most patients. This treatment offers a new option for progressive, radioiodine-resistant thyroid cancer.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Experiment Videos

Last Updated: Jul 4, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Area of Science:

Oncology
Pharmacology
Clinical Trials

Background:

Vascular endothelial growth factor (VEGF) expression correlates with aggressive differentiated thyroid cancer and poor outcomes.
Motesanib diphosphate (AMG 706) is an oral inhibitor targeting VEGF receptors, platelet-derived growth-factor receptor, and KIT.

Purpose of the Study:

To evaluate the efficacy and safety of motesanib diphosphate in patients with progressive, locally advanced or metastatic, radioiodine-resistant differentiated thyroid cancer.

Main Methods:

A phase 2, open-label, single-group study enrolled 93 patients with advanced differentiated thyroid cancer.
Patients received 125 mg of motesanib diphosphate orally once daily.
Primary endpoint was objective response rate; secondary endpoints included response duration, progression-free survival, safety, and serum thyroglobulin changes.

Main Results:

The objective response rate was 14%, with 67% achieving stable disease (35% for ≥24 weeks).
Median progression-free survival was 40 weeks (95% CI, 32-50).
81% of evaluable patients showed decreased serum thyroglobulin; common adverse events included diarrhea, hypertension, fatigue, and weight loss.

Conclusions:

Motesanib diphosphate demonstrated activity in advanced, progressive differentiated thyroid cancer, inducing partial responses and disease stabilization.
The study provides evidence for motesanib diphosphate as a treatment option for this patient population.